GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
- Conditions
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03697824
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT03693612
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1060
- Registration Number
- NCT03688620
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT03681951
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 502
- Registration Number
- NCT03674177
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 670
- Registration Number
- NCT03671369
- Locations
- 🇰🇷
GSK Investigational Site, Yangju-si, Gyeonggi-do, Korea, Republic of
First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 31
- Registration Number
- NCT03666988
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 996
- Registration Number
- NCT03652610
- Locations
- 🇮🇹
GSK Investigational Site, Massafra (TA), Italy
A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
- Conditions
- Interventions
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT03649412
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
A Clinical Study to Investigate the Dermal and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females With Sensitive Skin
- Conditions
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 90
- Registration Number
- NCT03640832
- Locations
- 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany